David Malcom Rodman - 09 Feb 2023 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Medical Officer
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
09 Feb 2023
Net transactions value
$0
Form type
4
Filing time
13 Feb 2023, 20:01:07 UTC
Next filing
21 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Award $0 +104,186 $0.000000 104,186 09 Feb 2023 Common Stock 104,186 $16.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

Remarks:

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).